Alcobra shares should be bought ahead of data, says Stifel

theflyonthewall.com

Stifel expects Alcobra to release top-line data from its first Phase 3 trial of MDX for adult inattentive-type ADHD in coming days. The firm is optimistic that the data will be strong and predicts that positive results would eventually position the drug as a strong alternative for adults with ADHD. It has a $30 price target and Buy rating on the shares.

View Comments (0)